Who is Zhittya Biomedical (Mauritius) International?
Who is Zhittya Biomedical (Mauritius) International?
Zhittya Biomedical (Mauritius) International is the Sub-Saharan Africa Regional Headquarters of Zhittya Genesis Medicine Inc., USA. Sub-Saharan Africa comprises 45 African Countries and a population of 1.1 billion (2020) and is expected to grow to 1.6 billion by 2025. The prevalence of Heart Disease, Diabetic Foot Ulcers, Parkinson's Disease, Alzheimer's Disease, and several other disorders are on the rise.
Zhittya Biomedical (Mauritius) International is the Sub-Saharan Africa Regional Headquarters of Zhittya Genesis Medicine Inc., USA. Sub-Saharan Africa comprises 45 African Countries and a population of 1.1 billion (2020) and is expected to grow to 1.6 billion by 2025. The prevalence of Heart Disease, Diabetic Foot Ulcers, Parkinson's Disease, Alzheimer's Disease, and several other disorders are on the rise.
Management:
Management:
Regional Partner: Kash Hurree
Regional Partner: Kash Hurree
Who Is Zhittya?
Who Is Zhittya?
Zhittya Genesis Medicine is a biotechnology company based in Las Vegas, Nevada. We are seeking to commercialize human FGF-1, a potent, naturally occurring growth factor. Since its discovery in the 1970s, FGF-1 has been extensively studied. Although very promising clinical results were achieved when FGF-1 was administered to patients with severe coronary artery disease and chronic diabetic foot ulcers, efforts to bring FGF-1 to market have largely been abandoned with no additional clinical testing reported since 2009. Zhittya's management believes that FGF-1 has the potential to be a revolutionary new biological drug for the treatment of numerous diseases characterized by a lack of blood flow to an organ or tissue. In fact, there are over 75 human diseases resulting from a lack of blood flow or perfusion to tissues and Zhittya has now targeted 19 of those disorders for treatment with FGF-1.
Zhittya Genesis Medicine is a biotechnology company based in Las Vegas, Nevada. We are seeking to commercialize human FGF-1, a potent, naturally occurring growth factor. Since its discovery in the 1970s, FGF-1 has been extensively studied. Although very promising clinical results were achieved when FGF-1 was administered to patients with severe coronary artery disease and chronic diabetic foot ulcers, efforts to bring FGF-1 to market have largely been abandoned with no additional clinical testing reported since 2009. Zhittya's management believes that FGF-1 has the potential to be a revolutionary new biological drug for the treatment of numerous diseases characterized by a lack of blood flow to an organ or tissue. In fact, there are over 75 human diseases resulting from a lack of blood flow or perfusion to tissues and Zhittya has now targeted 19 of those disorders for treatment with FGF-1.
Management:
Management:
CEO: Daniel Montano
CEO: Daniel Montano
President and CSO: Jack Jacobs
President and CSO: Jack Jacobs
Vice President of Strategic Innovations: Viktoryia Montano
Vice President of Strategic Innovations: Viktoryia Montano
Vice President of Corporate Affairs: Ernest Montano
Vice President of Corporate Affairs: Ernest Montano